Latest from Lisa Takagi
US private equity group to buy Japanese pharma firm in a transaction scheduled to close by September that marks owner's exit from pharma.
Mostly strong global sales of mainstay drugs, along with a forex boost, helped Japan's major pharma firms in the fiscal third quarter and calendar year.
While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.
Oncology-focused venture eyes potential US approval for first-line use as it kicks off expanded development of light-activated therapy.
Japan ships the first batch of 50,000 mpox vaccine doses to DRC after training local healthcare providers dealing with the persistent outbreak.
While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.